 Richard Duke
Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Apoptosis | 22 | 2012 | 2397 | 0.880 |
Why?
| | Membrane Glycoproteins | 18 | 2004 | 496 | 0.850 |
Why?
| | Fas Ligand Protein | 17 | 2012 | 60 | 0.700 |
Why?
| | T-Lymphocytes, Cytotoxic | 9 | 2006 | 177 | 0.630 |
Why?
| | Cytotoxicity, Immunologic | 11 | 2004 | 221 | 0.440 |
Why?
| | Genetic Therapy | 4 | 2012 | 313 | 0.380 |
Why?
| | fas Receptor | 8 | 2004 | 92 | 0.330 |
Why?
| | Killer Cells, Natural | 3 | 2004 | 470 | 0.330 |
Why?
| | Bone Neoplasms | 1 | 2012 | 255 | 0.310 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2006 | 130 | 0.290 |
Why?
| | Chromatin | 3 | 2004 | 554 | 0.280 |
Why?
| | Immunotherapy | 5 | 2010 | 662 | 0.270 |
Why?
| | Viral Hepatitis Vaccines | 1 | 2006 | 1 | 0.250 |
Why?
| | Viral Core Proteins | 1 | 2006 | 22 | 0.250 |
Why?
| | T-Lymphocytes | 11 | 2004 | 1984 | 0.250 |
Why?
| | Viral Nonstructural Proteins | 1 | 2006 | 65 | 0.240 |
Why?
| | Saccharomyces cerevisiae | 4 | 2010 | 579 | 0.230 |
Why?
| | Hepacivirus | 1 | 2006 | 243 | 0.220 |
Why?
| | Transplantation Immunology | 2 | 1999 | 29 | 0.220 |
Why?
| | Recombinant Fusion Proteins | 2 | 2006 | 667 | 0.210 |
Why?
| | Biological Assay | 1 | 2004 | 128 | 0.190 |
Why?
| | Adenoviridae | 3 | 2004 | 199 | 0.180 |
Why?
| | Graft Rejection | 3 | 2002 | 512 | 0.180 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2001 | 45 | 0.170 |
Why?
| | Tumor Cells, Cultured | 13 | 2003 | 881 | 0.170 |
Why?
| | DNA Damage | 3 | 2001 | 430 | 0.150 |
Why?
| | Prostatic Neoplasms | 4 | 1999 | 978 | 0.150 |
Why?
| | Animals | 38 | 2012 | 37948 | 0.150 |
Why?
| | Testis | 2 | 1999 | 162 | 0.140 |
Why?
| | Mice, Inbred BALB C | 8 | 2010 | 1251 | 0.130 |
Why?
| | Thymus Gland | 1 | 1999 | 311 | 0.130 |
Why?
| | Skin Neoplasms | 2 | 2002 | 850 | 0.130 |
Why?
| | Mice | 27 | 2010 | 18261 | 0.130 |
Why?
| | Bacterial Toxins | 2 | 1996 | 109 | 0.130 |
Why?
| | Endonucleases | 4 | 1988 | 34 | 0.120 |
Why?
| | Viral Proteins | 1 | 1999 | 353 | 0.120 |
Why?
| | DNA | 7 | 1994 | 1447 | 0.110 |
Why?
| | Melitten | 1 | 1994 | 1 | 0.100 |
Why?
| | Valinomycin | 1 | 1994 | 3 | 0.100 |
Why?
| | Calcimycin | 1 | 1994 | 36 | 0.100 |
Why?
| | Hemolysin Proteins | 1 | 1994 | 36 | 0.100 |
Why?
| | Dogs | 2 | 2012 | 438 | 0.090 |
Why?
| | Lymphocyte Activation | 6 | 2004 | 1124 | 0.090 |
Why?
| | Interleukin-2 | 5 | 1998 | 438 | 0.090 |
Why?
| | Transfection | 3 | 1999 | 924 | 0.090 |
Why?
| | Necrosis | 2 | 2012 | 243 | 0.090 |
Why?
| | Vaccines, Synthetic | 3 | 2010 | 138 | 0.090 |
Why?
| | Osteosarcoma | 1 | 2012 | 76 | 0.090 |
Why?
| | Serine Endopeptidases | 2 | 2006 | 129 | 0.090 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2010 | 68 | 0.080 |
Why?
| | Melanoma | 3 | 2003 | 757 | 0.080 |
Why?
| | Calcium | 3 | 1994 | 1182 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2002 | 1129 | 0.080 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 127 | 0.070 |
Why?
| | Cancer Vaccines | 1 | 2010 | 160 | 0.070 |
Why?
| | Major Histocompatibility Complex | 1 | 1989 | 233 | 0.070 |
Why?
| | AIDS Vaccines | 2 | 2001 | 53 | 0.070 |
Why?
| | Cytoplasmic Granules | 1 | 1988 | 76 | 0.070 |
Why?
| | Cell Line | 7 | 1998 | 2821 | 0.070 |
Why?
| | Nucleoside-Triphosphatase | 1 | 2006 | 14 | 0.060 |
Why?
| | Neoplasms, Experimental | 2 | 2004 | 167 | 0.060 |
Why?
| | Ionomycin | 2 | 2004 | 22 | 0.060 |
Why?
| | DEAD-box RNA Helicases | 1 | 2006 | 89 | 0.060 |
Why?
| | Lymphocyte Depletion | 1 | 1986 | 133 | 0.060 |
Why?
| | Mice, Inbred Strains | 4 | 2004 | 396 | 0.060 |
Why?
| | Yeasts | 1 | 2005 | 51 | 0.050 |
Why?
| | Mice, Inbred C57BL | 6 | 2010 | 5967 | 0.050 |
Why?
| | HeLa Cells | 1 | 2006 | 632 | 0.050 |
Why?
| | Autoimmunity | 2 | 2004 | 930 | 0.050 |
Why?
| | Lymphocytes | 4 | 1998 | 379 | 0.050 |
Why?
| | Ionophores | 1 | 2004 | 21 | 0.050 |
Why?
| | Egtazic Acid | 1 | 2004 | 37 | 0.050 |
Why?
| | DNA Fragmentation | 1 | 2004 | 39 | 0.050 |
Why?
| | Molecular Sequence Data | 5 | 2010 | 2909 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2004 | 120 | 0.050 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2004 | 150 | 0.050 |
Why?
| | Hepatitis C | 1 | 2006 | 254 | 0.050 |
Why?
| | Chelating Agents | 1 | 2004 | 72 | 0.050 |
Why?
| | Cell Survival | 4 | 1991 | 1092 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 272 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2004 | 254 | 0.050 |
Why?
| | Cell Division | 3 | 2002 | 753 | 0.050 |
Why?
| | Ultraviolet Rays | 2 | 2004 | 384 | 0.050 |
Why?
| | Membrane Proteins | 1 | 1989 | 1159 | 0.050 |
Why?
| | Arthritis, Experimental | 1 | 2004 | 141 | 0.050 |
Why?
| | Dog Diseases | 1 | 2003 | 70 | 0.050 |
Why?
| | Glucocorticoids | 3 | 1999 | 528 | 0.050 |
Why?
| | Genes, ras | 1 | 2002 | 96 | 0.050 |
Why?
| | Microscopy | 1 | 2004 | 148 | 0.050 |
Why?
| | Cytokines | 3 | 2006 | 2045 | 0.050 |
Why?
| | Fluorescent Dyes | 1 | 2004 | 333 | 0.040 |
Why?
| | PUVA Therapy | 1 | 2001 | 6 | 0.040 |
Why?
| | Immunity, Cellular | 2 | 2001 | 272 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2002 | 407 | 0.040 |
Why?
| | Perforin | 2 | 1992 | 21 | 0.040 |
Why?
| | Pore Forming Cytotoxic Proteins | 2 | 1992 | 15 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2001 | 161 | 0.040 |
Why?
| | Humans | 23 | 2006 | 144671 | 0.040 |
Why?
| | DNA Primers | 3 | 1996 | 507 | 0.040 |
Why?
| | Flow Cytometry | 3 | 1999 | 1154 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2004 | 1437 | 0.040 |
Why?
| | Antigens | 2 | 1992 | 347 | 0.040 |
Why?
| | Base Sequence | 4 | 1996 | 2177 | 0.040 |
Why?
| | B-Lymphocytes | 2 | 1996 | 875 | 0.040 |
Why?
| | HIV-1 | 2 | 1996 | 897 | 0.040 |
Why?
| | MAP Kinase Kinase Kinase 1 | 1 | 1999 | 18 | 0.040 |
Why?
| | Lung Neoplasms | 3 | 2004 | 2660 | 0.040 |
Why?
| | Immediate-Early Proteins | 1 | 1999 | 46 | 0.040 |
Why?
| | Phosphoprotein Phosphatases | 1 | 1999 | 65 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2002 | 454 | 0.040 |
Why?
| | Lymphoma | 3 | 1998 | 233 | 0.040 |
Why?
| | Poxviridae | 1 | 1999 | 3 | 0.040 |
Why?
| | Cell Transplantation | 1 | 1999 | 39 | 0.040 |
Why?
| | Myocarditis | 1 | 2000 | 101 | 0.040 |
Why?
| | I-kappa B Proteins | 1 | 1999 | 74 | 0.040 |
Why?
| | Serpins | 1 | 1999 | 28 | 0.040 |
Why?
| | Spheroids, Cellular | 1 | 1999 | 74 | 0.040 |
Why?
| | Transplantation, Heterologous | 1 | 1999 | 169 | 0.040 |
Why?
| | Mice, Nude | 2 | 1999 | 677 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 3523 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 1999 | 131 | 0.030 |
Why?
| | Receptors, Virus | 1 | 1998 | 96 | 0.030 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 1999 | 167 | 0.030 |
Why?
| | Depsipeptides | 1 | 1998 | 15 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1999 | 452 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2001 | 451 | 0.030 |
Why?
| | Toxoplasma | 1 | 1998 | 49 | 0.030 |
Why?
| | Cell Nucleus | 3 | 1994 | 592 | 0.030 |
Why?
| | Immunoglobulin M | 2 | 1998 | 281 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2001 | 498 | 0.030 |
Why?
| | Cell Death | 2 | 2004 | 382 | 0.030 |
Why?
| | HIV Envelope Protein gp160 | 1 | 1996 | 4 | 0.030 |
Why?
| | Molecular Weight | 2 | 1989 | 312 | 0.030 |
Why?
| | Male | 12 | 2004 | 72431 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 1996 | 200 | 0.030 |
Why?
| | Superantigens | 1 | 1996 | 70 | 0.030 |
Why?
| | Enterotoxins | 1 | 1996 | 89 | 0.030 |
Why?
| | Tissue Transplantation | 1 | 1995 | 9 | 0.030 |
Why?
| | Neoplasms | 2 | 2005 | 2873 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 1996 | 106 | 0.030 |
Why?
| | Sertoli Cells | 1 | 1995 | 28 | 0.030 |
Why?
| | HIV Envelope Protein gp120 | 1 | 1995 | 55 | 0.030 |
Why?
| | Endodeoxyribonucleases | 2 | 1986 | 77 | 0.030 |
Why?
| | Cell Cycle | 1 | 1998 | 595 | 0.030 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 1995 | 20 | 0.030 |
Why?
| | NF-kappa B | 1 | 1999 | 657 | 0.030 |
Why?
| | Rats | 2 | 1999 | 5570 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 1999 | 628 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1996 | 235 | 0.030 |
Why?
| | Alopecia Areata | 1 | 1995 | 13 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2001 | 835 | 0.030 |
Why?
| | RNA, Messenger | 3 | 2002 | 2815 | 0.030 |
Why?
| | Hair | 1 | 1995 | 86 | 0.030 |
Why?
| | Cells, Cultured | 4 | 2001 | 4110 | 0.030 |
Why?
| | Receptors, Complement | 1 | 1995 | 125 | 0.030 |
Why?
| | Virus Diseases | 1 | 1996 | 218 | 0.030 |
Why?
| | Mutation | 2 | 2004 | 4081 | 0.030 |
Why?
| | Salmonella typhimurium | 1 | 1995 | 189 | 0.030 |
Why?
| | Immunization | 1 | 1995 | 374 | 0.030 |
Why?
| | Models, Biological | 1 | 2001 | 1811 | 0.030 |
Why?
| | Heart Diseases | 1 | 1996 | 341 | 0.020 |
Why?
| | Recombinant Proteins | 3 | 2004 | 1363 | 0.020 |
Why?
| | Spleen | 1 | 1995 | 510 | 0.020 |
Why?
| | Mitochondria | 1 | 1999 | 984 | 0.020 |
Why?
| | Fetus | 1 | 1996 | 800 | 0.020 |
Why?
| | Peptides | 1 | 1998 | 989 | 0.020 |
Why?
| | Mice, Transgenic | 3 | 2002 | 2184 | 0.020 |
Why?
| | Mice, Inbred DBA | 2 | 2004 | 187 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 1998 | 923 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2136 | 0.020 |
Why?
| | Protein Biosynthesis | 2 | 1984 | 455 | 0.020 |
Why?
| | Zinc | 2 | 1984 | 295 | 0.020 |
Why?
| | Leukemia, Experimental | 1 | 2010 | 27 | 0.020 |
Why?
| | Genes, MHC Class I | 1 | 2010 | 37 | 0.020 |
Why?
| | Enzyme Activation | 2 | 1999 | 762 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1046 | 0.020 |
Why?
| | Cardiomegaly | 2 | 2002 | 174 | 0.020 |
Why?
| | Skin | 1 | 1995 | 762 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2001 | 2201 | 0.020 |
Why?
| | Dexamethasone | 2 | 1999 | 366 | 0.020 |
Why?
| | Lectins | 1 | 1989 | 45 | 0.020 |
Why?
| | Terminology as Topic | 1 | 1991 | 255 | 0.020 |
Why?
| | Mast-Cell Sarcoma | 1 | 1988 | 6 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 1988 | 57 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2010 | 768 | 0.020 |
Why?
| | Species Specificity | 1 | 1989 | 573 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 849 | 0.020 |
Why?
| | Kidney | 1 | 1995 | 1495 | 0.020 |
Why?
| | Oligosaccharides | 1 | 1988 | 60 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1991 | 667 | 0.020 |
Why?
| | Cell Separation | 1 | 1988 | 303 | 0.020 |
Why?
| | Histocompatibility Antigens | 1 | 1988 | 102 | 0.020 |
Why?
| | Magnesium | 2 | 1985 | 155 | 0.020 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1986 | 49 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 2002 | 1246 | 0.020 |
Why?
| | Models, Molecular | 1 | 2010 | 1610 | 0.010 |
Why?
| | Urethane | 1 | 2004 | 43 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1984 | 25 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2004 | 158 | 0.010 |
Why?
| | Adoptive Transfer | 1 | 2004 | 197 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1984 | 182 | 0.010 |
Why?
| | Antibodies | 2 | 1996 | 396 | 0.010 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1988 | 643 | 0.010 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2002 | 19 | 0.010 |
Why?
| | Corticosterone | 1 | 1984 | 242 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1996 | 1047 | 0.010 |
Why?
| | Adenoma | 1 | 2004 | 218 | 0.010 |
Why?
| | Myosin Heavy Chains | 1 | 2002 | 183 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 973 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2003 | 572 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 370 | 0.010 |
Why?
| | HIV Infections | 1 | 1995 | 3148 | 0.010 |
Why?
| | Down-Regulation | 1 | 2002 | 616 | 0.010 |
Why?
| | Cell Size | 1 | 2000 | 92 | 0.010 |
Why?
| | Kinetics | 1 | 1983 | 1603 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 10 | 1 | 1999 | 4 | 0.010 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 1999 | 6 | 0.010 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 1999 | 23 | 0.010 |
Why?
| | Metallothionein | 1 | 1999 | 25 | 0.010 |
Why?
| | Phagocytosis | 2 | 1992 | 296 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1999 | 29 | 0.010 |
Why?
| | Gene Dosage | 1 | 2000 | 148 | 0.010 |
Why?
| | Protein Phosphatase 1 | 1 | 1999 | 32 | 0.010 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 1999 | 49 | 0.010 |
Why?
| | Mitogens | 1 | 1999 | 55 | 0.010 |
Why?
| | Transcription, Genetic | 2 | 1996 | 1468 | 0.010 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 1999 | 70 | 0.010 |
Why?
| | Hybridomas | 1 | 1999 | 233 | 0.010 |
Why?
| | Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 1998 | 8 | 0.010 |
Why?
| | Membrane Potentials | 1 | 1999 | 278 | 0.010 |
Why?
| | Thymoma | 1 | 1998 | 37 | 0.010 |
Why?
| | Thymus Neoplasms | 1 | 1998 | 30 | 0.010 |
Why?
| | Caspases | 1 | 1999 | 229 | 0.010 |
Why?
| | CD3 Complex | 1 | 1998 | 111 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2002 | 733 | 0.010 |
Why?
| | Cycloheximide | 1 | 1998 | 42 | 0.010 |
Why?
| | Dactinomycin | 1 | 1998 | 23 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 1999 | 287 | 0.010 |
Why?
| | Androgens | 1 | 1999 | 178 | 0.010 |
Why?
| | Gamma Rays | 1 | 1998 | 56 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1998 | 252 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1998 | 364 | 0.010 |
Why?
| | Myocardium | 1 | 2002 | 928 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2000 | 475 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1998 | 334 | 0.010 |
Why?
| | Proprotein Convertase 5 | 1 | 1996 | 1 | 0.010 |
Why?
| | Ligands | 1 | 1998 | 662 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1999 | 431 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1996 | 273 | 0.010 |
Why?
| | Models, Immunological | 1 | 1996 | 100 | 0.010 |
Why?
| | Multigene Family | 1 | 1996 | 210 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 1998 | 691 | 0.010 |
Why?
| | Exudates and Transudates | 1 | 1995 | 12 | 0.010 |
Why?
| | HIV Antibodies | 1 | 1995 | 61 | 0.010 |
Why?
| | Receptor Aggregation | 1 | 1995 | 10 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1996 | 535 | 0.010 |
Why?
| | Proto-Oncogenes | 1 | 1995 | 28 | 0.010 |
Why?
| | Peritoneum | 1 | 1995 | 44 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1995 | 146 | 0.010 |
Why?
| | Rabbits | 1 | 1996 | 651 | 0.010 |
Why?
| | Antibody Formation | 1 | 1996 | 291 | 0.010 |
Why?
| | Signal Transduction | 2 | 1998 | 5185 | 0.010 |
Why?
| | Reference Values | 1 | 1996 | 794 | 0.010 |
Why?
| | Plasmids | 1 | 1995 | 375 | 0.010 |
Why?
| | Mammals | 1 | 1996 | 296 | 0.010 |
Why?
| | Epidermis | 1 | 1995 | 157 | 0.010 |
Why?
| | Gene Expression | 1 | 1999 | 1476 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 1998 | 1465 | 0.010 |
Why?
| | Keratinocytes | 1 | 1995 | 250 | 0.010 |
Why?
| | Adult | 1 | 1996 | 40489 | 0.010 |
Why?
| | Administration, Oral | 1 | 1995 | 851 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1996 | 781 | 0.010 |
Why?
| | Age Factors | 1 | 2000 | 3329 | 0.010 |
Why?
| | Staphylococcus aureus | 1 | 1996 | 454 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1996 | 886 | 0.010 |
Why?
| | Immunity, Innate | 1 | 1998 | 843 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2019 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 1999 | 1484 | 0.010 |
Why?
| | Phenotype | 1 | 1999 | 3147 | 0.010 |
Why?
| | CD4 Antigens | 1 | 1991 | 137 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 1995 | 675 | 0.000 |
Why?
| | Neoplasm Transplantation | 1 | 1988 | 246 | 0.000 |
Why?
| | Clone Cells | 1 | 1988 | 263 | 0.000 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1928 | 0.000 |
Why?
| | Interphase | 1 | 1985 | 38 | 0.000 |
Why?
| | Female | 2 | 2004 | 78304 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1988 | 1505 | 0.000 |
Why?
|
|
Duke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|